Beam Therapeutics, trading on NASDAQ under the symbol BEAM, is a biotechnology company focused on developing precision genetic medicines through base editing. Unlike traditional gene editing methods that rely on double-stranded DNA breaks, Beam’s proprietary base editing technology enables the direct, irreversible conversion of one DNA base into another, offering the potential for safer and more efficient treatments. The company’s platform is designed to address a wide range of genetic diseases by correcting single-nucleotide mutations at their source.
The company’s pipeline spans therapeutic areas including rare blood disorders, oncology, and liver diseases. Lead programs include base editing approaches for sickle cell disease and β-thalassemia, as well as novel immuno-oncology candidates that engineer immune cells to better recognize and destroy tumor cells. Many of Beam’s assets are in preclinical stages, with select programs advancing toward clinical trials under established regulatory pathways.
Beam Therapeutics collaborates with leading biopharma partners to accelerate the development and commercialization of its candidates. Strategic alliances with companies such as Pfizer and F. Hoffmann-La Roche provide access to complementary expertise, global development resources, and expanded manufacturing capabilities. Headquartered in Cambridge, Massachusetts, Beam also maintains research and production facilities in the United States and works with international partners to potentially extend its therapies worldwide.
Founded in 2017 by scientists from Harvard University and MIT, Beam Therapeutics was co-founded by pioneers in genome engineering, including David Liu and J. Keith Joung. The company is led by CEO John Evans, who has brought extensive experience in biopharmaceutical development and commercialization. Under his leadership, Beam has grown its scientific team, enhanced its intellectual property portfolio, and established a clear roadmap for bringing next-generation genetic medicines to patients.
AI Generated. May Contain Errors.
